Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Marker Therapeutics (MRKR) Return on Sales (2016 - 2025)

Marker Therapeutics (MRKR) has disclosed Return on Sales for 8 consecutive years, with 1.62% as the latest value for Q3 2025.

  • On a quarterly basis, Return on Sales fell 42.0% to 1.62% in Q3 2025 year-over-year; TTM through Sep 2025 was 8.47%, a 810.0% increase, with the full-year FY2024 number at 53.66%, down 5541.0% from a year prior.
  • Return on Sales was 1.62% for Q3 2025 at Marker Therapeutics, up from 4.8% in the prior quarter.
  • In the past five years, Return on Sales ranged from a high of 8.27% in Q2 2023 to a low of 66.41% in Q1 2021.
  • A 5-year average of 10.27% and a median of 1.5% in 2025 define the central range for Return on Sales.
  • Peak YoY movement for Return on Sales: soared 5626bps in 2022, then tumbled -3435bps in 2023.
  • Marker Therapeutics' Return on Sales stood at 66.41% in 2021, then soared by 98bps to 1.07% in 2022, then crashed by -3208bps to 35.43% in 2023, then skyrocketed by 103bps to 0.92% in 2024, then plummeted by -277bps to 1.62% in 2025.
  • Per Business Quant, the three most recent readings for MRKR's Return on Sales are 1.62% (Q3 2025), 4.8% (Q2 2025), and 12.74% (Q1 2025).